Collegium Pharmaceutical (FRA:354) Short Interest


FRA:354 Collegium Pharmaceutical Inc FRA:354
75 GF Score
Price €31.20
GF Value €37.18
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Collegium Pharmaceutical Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

FRA:354 vs ALVO, PAHC, BIOA: Short Interest Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Collegium Pharmaceutical's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Collegium Pharmaceutical Short Interest vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Collegium Pharmaceutical's Short Interest distribution charts can be found below:

* The bar in red indicates where Collegium Pharmaceutical's Short Interest falls into.


FRA:354
75GF Score
Collegium Pharmaceutical Inc FRA:354
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Collegium Pharmaceutical (FRA:354) Overvalued in 2026?

Based on GuruFocus' analysis, Collegium Pharmaceutical stock appears to be undervalued. The current stock price of €31.20 is trading 16.1% below its estimated GF Value™ of €37.18. GuruFocus considers Collegium Pharmaceutical to be Modestly Undervalued.

Key valuation signals for FRA:354:

  • Short Interest:
  • GF Value™: €37.18 vs. price of €31.20 (16.1% below fair value)
  • GF Score™: 75/100 with 3 warning signs

No single metric tells the full story. See the FRA:354 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Collegium Pharmaceutical Business Description

Other Exchanges COLL:USA354:Germany
Address 100 Technology Center Drive, Stoughton, MA, USA, 02072
Collegium Pharmaceutical Inc is a diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. The company has developed, licensed, and acquired a portfolio of meaningfully differentiated products for the treatment of attention deficit hyperactivity disorder (ADHD) and moderate to severe pain. It commercializes its products in the United States, including Jornay PM, Belbuca, Xtampza ER, Nucynta ER, Nucynta IR (collectively, the Nucynta Products), and Symproic. The company's product portfolio includes Jornay PM, Belbuca, Xtampza ER, Nucynta IR, Nucynta ER, and Symproic.
75GF Score

Get the complete analysis for FRA:354

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€31.20
Price
€37.18
GF Value